Table 1.
Baseline characteristics of patients.
| Characteristics | Patients, No. (%) |
P-value | |
|---|---|---|---|
| Control (n = 40) | Aspirin (n = 40) | ||
| General status | |||
| Age, years | 0.356 | ||
| ≤50 | 27 (67.5) | 23 (57.5) | |
| >50 | 13 (32.5) | 17 (42.5) | |
| Sex | 1.000 | ||
| Male | 37 (92.5) | 37 (92.5) | |
| Female | 3 (7.5) | 3 (7.5) | |
| ECOG performance status | 0.340 | ||
| 0 | 29 (72.5) | 25 (62.5) | |
| 1 | 11 (27.5) | 15 (37.5) | |
| Laboratory findings | |||
| Viral serology | |||
| Positive for HBsAg | 35 (87.5) | 37 (92.5) | 0.456 |
| Positive for HBeAg | 11 (27.5) | 11 (27.5) | 1.000 |
| HBV DNA load, IU/mL | 0.654 | ||
| <2000 | 18 (45.0) | 20 (50.0) | |
| ≥2000 | 22 (55.0) | 20 (50.0) | |
| Anti-viral treatment, yes | 11 (27.5) | 8 (20.0) | 0.431 |
| AFP, ng/ml | 0.648 | ||
| <400 | 15 (37.5) | 17 (42.5) | |
| ≥400 | 25 (62.5) | 23 (57.5) | |
| Total bilirubin, μmol/L | 0.171 | ||
| ≤17.1 | 21 (52.5) | 27 (67.5) | |
| >17.1 | 19 (47.5) | 13 (32.5) | |
| Albumin, g/L | 0.166 | ||
| <35 | 4 (10.0) | 1 (2.5) | |
| ≥35 | 36 (90.0) | 39 (97.5) | |
| ALT, U/L | 0.228 | ||
| ≤44 | 25 (62.5) | 30 (75.0) | |
| >44 | 15 (37.5) | 10 (25.0) | |
| Prothrombin time, s | 0.152 | ||
| ≤13 | 30 (75.0) | 35 (87.5) | |
| >13 | 10 (25.0) | 5 (12.5) | |
| Platelet count, × 109/L | 0.329 | ||
| <100 | 10 (25.0) | 14 (35.0) | |
| ≥100 | 30 (75.0) | 26 (65.0) | |
| Surgical findings | |||
| Type of hepatectomy | 0.469 | ||
| Major | 29 (72.5) | 26 (65.0) | |
| Minor | 11 (27.5) | 14 (35.0) | |
| Anatomic resection, yes | 14 (35.0) | 16 (40.0) | 0.644 |
| Hilar clamping time, minutes | 0.531 | ||
| <15 | 5 (12.5) | 7 (17.5) | |
| ≥15 | 35 (87.5) | 33 (82.5) | |
| Intraoperative blood loss, mL | 0.813 | ||
| ≤800 | 26 (65.0) | 27 (67.5) | |
| >800 | 14 (35.0) | 13 (32.5) | |
| PVTT types | 0.469 | ||
| Ⅰ | 4 (10.0) | 9 (22.5) | |
| Ⅱ | 23 (57.5) | 18 (45.0) | |
| Ⅲ | 11 (27.5) | 11 (27.5) | |
| Ⅳ | 2 (5.0) | 2 (5.0) | |
| Pathologic findings | |||
| Tumor diameter, cm | 0.340 | ||
| >5 | 29 (72.5) | 25 (62.5) | |
| ≤5 | 11 (27.5) | 15 (37.5) | |
| Tumor number | 0.644 | ||
| Multiple | 2 (5.0%) | 3 (7.5%) | |
| Single | 38 (95.0%) | 37 (92.5%) | |
| Tumor encapsulation | 0.592 | ||
| No/Incomplete | 30 (75.0) | 32 (80.0) | |
| Complete | 10 (25.0) | 8 (20.0) | |
| Satellite nodules, yes | 24 (60.0) | 22 (55.0) | 0.651 |
| Liver cirrhosis, yes | 8 (20.0) | 7 (17.5) | 0.775 |
| Microvascular invasion, yes | 37 (92.5) | 36 (90.0) | 0.692 |
| Recurrence findings | |||
| Primary tumor recurrence | 0.793 | ||
| Yes | 30 (75.0) | 31 (77.5) | |
| No | 10 (25.0) | 9 (22.5) | |
| PVTT recurrence | 0.045 | ||
| Yes | 36 (90.0) | 29 (72.5) | |
| No | 4 (10.0) | 11 (27.5) | |
Abbreviations: ECOG, Eastern Cooperative Oncology Group; AFP, α-fetoprotein; ALT, alanine aminotransferase; PVTT, portal vein tumor thrombus.